| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000031854 |
| Receipt No. | R000036373 |
| Official scientific title of the study | Non-randomized controlled trial assessing the usefulness of new diagnostic and therapeutic algorithms for prolonged cough |
| Date of disclosure of the study information | 2018/03/23 |
| Last modified on | 2018/03/30 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Non-randomized controlled trial assessing the usefulness of new diagnostic and therapeutic algorithms for prolonged cough | |
| Title of the study (Brief title) | NHOM-Cough | |
| Region |
|
|
| Condition | |||
| Condition | Cough | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To clarify contribution of an algorithm to earlier cough improvement by defining the procedures for diagnosing the cause of prolonged cough as a novel diagnosis/treatment algorithm after defining the treatment sequence and conducting a therapeutic diagnosis. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Number of days required to be judged as cough improved since first visit (improvement of VAS 60% or more maintained for more than 3 days) |
| Key secondary outcomes | 1) Frequency of cases judged to have improved cough
2) Clinical diagnosis on the cause of cough 3) Adverse events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | Registered cases for 1 year from the start of the study will be allocated to the control group in which we perform diagnosis and treatment based on the guidelines. Treatment in two or more disease states cannot be performed. Also, the use of antitussive agent which is symptomatic treatment is not allowed. | |
| Interventions/Control_2 | After an interval of 5 months from the end of registration of the control group, registered cases for 1 year will be allocated to the intervention group in which we perform a therapeutic diagnosis according to the prescribed diagnostic and treatment algorithm. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Aged 20 to 75 at the time of case registration
(2) First-visit patients whose main complaint is cough (currently not in hospital with other respiratory diseases in the department) (3) Patients with cough lasting more than 3 weeks accompanying little sputum (4) Whose VAS of the cough in the last week at the visit is 5 cm or more (5) Provided informed consent to various examinations, medical questionnaires, cough diary entries of up to 10 weeks after the start of control/intervention period, drug restrictions related to diagnostic treatment and antitussive agent, and provided written consent for participation in this study |
|||
| Key exclusion criteria | (1) Confirmed obvious cough improvement naturally or by treatment during the course before visit
(2) Having a history of treatment as asthma including cough asthma within three years besides this episode (3) Having a history or complications of chronic respiratory/heart/kidney disease, GERD, autoimmune /inflammatory bowel disease, tonsil hypertrophy, or laryngeal disease (4) Pregnant or possibly pregnant (5) Having a history of drug irritation or severe side effects to macrolide antibiotics, PPI, ICS, H1 blocker, H2 blocker, or beta stimulant (6) Confirmed pulmonary shadow abnormality or obvious heart expansion in chest X-ray (7) With obvious airway infection symptoms (fever of 37.5 degree Celsius. or higher or purulent sputum) at the initial visit to the institution (8) Whose Brinkman Index (average number of smokers per day x total smoking years) is 400 or more (9) With the rale sound by consultation including mild rales and forced expiration. (To listen carefully to mild twisting sounds in the lower lungs and auscultation with mild wheezing (10) Using ACE inhibitors (but can enter at 2 weeks or later after discontinuation) (11) Taking orally H2 blockers, PPI, oral steroids, systemic immunosuppressants or psychotropic drugs for some underlying disease (12) Others where the attending doctor judged inappropriate to participate in this study |
|||
| Target sample size | 500 | |||
| Research contact person | |
| Name of lead principal investigator | Kiyoshi Sekiya |
| Organization | NHO Sagamihara National Hospital |
| Division name | Allergology |
| Address | Sakuradai 18-1, Minami-ku, Sagamihara-shi, Kanagawa, 252-0392, Japan |
| TEL | 042-742-8311 |
| k-sekiya@sagamihara-hosp.gr.jp | |
| Public contact | |
| Name of contact person | Kiyoshi Sekiya |
| Organization | NHO Sagamihara National Hospital |
| Division name | Allergology |
| Address | Sakuradai 18-1, Minami-ku, Sagamihara-shi, Kanagawa, 252-0392, Japan |
| TEL | 042-742-8311 |
| Homepage URL | |
| k-sekiya@sagamihara-hosp.gr.jp | |
| Sponsor | |
| Institute | Sagamihara National Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Hospital Organization |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 相模原病院(神奈川県)、東京病院(東京都)、名古屋医療センター(愛知県)、金沢医療センター(石川県)、南岡山医療センター(岡山県)、福岡病院(福岡県)、沖縄病院(沖縄県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036373 |